PLX8394 is an orally active inhibitor of serine/threonine-protein kinase B-Raf (BRAF) protein. PLX8394 can selectively bind to and inhibit the activity of both wild-type and mutated forms of BRAF, then inhibit the proliferation of tumor cells which express mutated forms of BRAF. PLX8394 appears to be effective against tumors that express multiple mutated forms of […]
More Information Supplier Page
NIH-12848 is a putative inhibitor of phosphatidylinositol 5-phosphate 4-kinase γ (PI5P4Kγ) with an IC50 of 1 μM.
More Information Supplier Page
NIH-12848 is a putative inhibitor of phosphatidylinositol 5-phosphate 4-kinase γ (PI5P4Kγ) with an IC50 of 1 μM.
More Information Supplier Page NIH-12848 is a putative inhibitor of phosphatidylinositol 5-phosphate 4-kinase γ (PI5P4Kγ) with an IC50 of 1 μM.
More Information Supplier Page NIH-12848 is a putative inhibitor of phosphatidylinositol 5-phosphate 4-kinase γ (PI5P4Kγ) with an IC50 of 1 μM.
More Information Supplier Page NIH-12848 is a putative inhibitor of phosphatidylinositol 5-phosphate 4-kinase γ (PI5P4Kγ) with an IC50 of 1 μM.
More Information Supplier Page 
(RS)-MCPG is a non-selective group I/II metabotropic glutamate receptor antagonist.
More Information Supplier Page
E4CPG is a novel group I/II metabotropic glutamate receptor antagonist, more potent than (RS)-MCPG.
More Information Supplier Page
E4CPG is a novel group I/II metabotropic glutamate receptor antagonist, more potent than (RS)-MCPG.
More Information Supplier Page E4CPG is a novel group I/II metabotropic glutamate receptor antagonist, more potent than (RS)-MCPG.
More Information Supplier Page 
